Dr. David W. Brown, M.D.
Psychiatry (Psychiatry Physician)
At a glance
- In the NPI registry since
- 2007
Licensed in Texas since 1987, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
TX license H2267 (first issued 1987; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluoxetine Hcl Other prescribers in Austin, TX | 25 |
| Pregabalin Other prescribers in Austin, TX | 25 |
| Olanzapine Other prescribers in Austin, TX | 24 |
| Lorazepam Other prescribers in Austin, TX | 20 |
| Alprazolam Other prescribers in Austin, TX | 16 |
| Clozapine Odt (clozapine) Other prescribers in Austin, TX | 16 |
| Gabapentin Other prescribers in Austin, TX | 15 |
| Mirtazapine Other prescribers in Austin, TX | 14 |
| Trintellix (vortioxetine hydrobromide) Other prescribers in Austin, TX | 14 |
| Clonazepam Other prescribers in Austin, TX | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 34 payments worth $8,450 in total to this clinician.
| Compensation for services other than consulting (speaking, faculty) | $6,645 |
|---|---|
| Travel and Lodging | $940 |
| Food and Beverage | $865 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) COBENFY · Neuroscience | $2,215 |
| E.r. Squibb & Sons, L.l.c. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) COBENFY · Neuroscience | $2,215 |
| E.r. Squibb & Sons, L.l.c. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) COBENFY · Neuroscience | $2,215 |
| E.r. Squibb & Sons, L.l.c. Oct 9, 2025 | Travel and Lodging COBENFY · Neuroscience · travel to Dallas, TX | $562 |
| E.r. Squibb & Sons, L.l.c. Oct 9, 2025 | Travel and Lodging COBENFY · Neuroscience · travel to Dallas, TX | $326 |
| E.r. Squibb & Sons, L.l.c. Oct 9, 2025 | Travel and Lodging COBENFY · Neuroscience · travel to Dallas, TX | $51.73 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 7 companies. The companies reported $1,860,847 in research payments for these studies, mostly to the institutions running them.
- A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended…
Teva Pharmaceuticals USA, Inc. - A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
AbbVie Inc. · Completed · NCT05227703 - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
E.r. Squibb & Sons, L.l.c. - An adaptive two-part randomized, double blind, placebo-controlled Phase 2 study to assess the safety, tolerability, pharmacokinetics, and efficacy of emraclidine in participants with schizophrenia
AbbVie Inc. - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - An Open-label, Phase 1, Single Ascending Dose Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of KarXT Intramuscular Formulations in Participants with Schizophrenia
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder…
E.r. Squibb & Sons, L.l.c. - A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
AbbVie Inc. · Recruiting · NCT07145918 - A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
AbbVie Inc. · Terminated · NCT05443724 - An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.